All relevant data are within the paper and its Supporting Information files.

Introduction {#sec004}
============

Chagas disease is a neglected tropical disease that is caused by the flagellated protozoan parasite *Trypanosoma cruzi* and that is primarily transmitted by blood-sucking triatomines \[[@pone.0150996.ref001]\]. Approximately 10 million people are infected worldwide, with approximately 40,000 new cases occurring every year, and the estimated burden of this disease in terms of disability-adjusted life years (DALYs) is 586,000 \[[@pone.0150996.ref001],[@pone.0150996.ref002]\]. After the acute phase, 70--80% of infected people remain asymptomatic throughout their lives, whereas the other 20--30% develop chronic cardiac or digestive diseases, which can lead to death \[[@pone.0150996.ref001],[@pone.0150996.ref002]\]. Unfortunately, beyond vector control measures, no prophylactic measures currently exist, and the available treatments are not only toxic but also have not been proven to be effective in cases of chronic chagasic patients \[[@pone.0150996.ref001],[@pone.0150996.ref002]\].

CD8^+^ T cells are a critical component of the protective immune response against the intracellular parasite *T*. *cruzi* \[[@pone.0150996.ref003]\]. The depletion of CD8^+^ T cells in animal models of *T*. *cruzi* acute infection demonstrated the role of these cells in infection control. For example, in CD8^+^ T cell-depleted mice, the disease develop faster, and these animals have higher parasitemia levels than wild-type infected mice \[[@pone.0150996.ref004]--[@pone.0150996.ref008]\]. CD8^+^ T cell activation occurs when cells specifically recognize short peptides (8 to 10 amino acids in length), which are usually derived from intracellular proteins and which are presented in the context of the major histocompatibility complex class I (MHC I) molecules \[[@pone.0150996.ref009]--[@pone.0150996.ref011]\]. Whereas peptide binding to MHC I molecules occurs through an interaction between the side chains of the peptide amino acids and the binding pockets of the MHC I molecule, the peptide-binding affinity is usually determined by an interaction between the amino acids located on the N- and C-termini of the peptide with the B and F pockets of the class I molecules \[[@pone.0150996.ref012],[@pone.0150996.ref013]\]. Class I molecules are grouped into diverse clusters or supertypes that share similarities in their peptide-binding pockets. Thus, HLA supertypes are defined as a set of alleles with potentially similar binding pockets that allow the binding of related peptides \[[@pone.0150996.ref013],[@pone.0150996.ref014]\]. At least nine MHC class I supertypes have been described: A1, A2, A3, A24, B7, B27, B44, B58 and B62 \[[@pone.0150996.ref013]--[@pone.0150996.ref015]\].

The frequencies of HLA alleles vary greatly among different populations; thus, obtaining knowledge regarding these alleles is a critical step in the development of potential therapeutic or prophylactic immune strategies that require population-wide coverage. In this context, promiscuous peptides, which are defined as peptides that can be presented by different HLA molecules belonging to the same MHC \[[@pone.0150996.ref016]\] or even different MHC supertypes, are attractive targets for immunotherapy \[[@pone.0150996.ref017]--[@pone.0150996.ref020]\].

Our group recently reported that the TcTLE peptide (previously named K1 peptide) from the KMP-11 protein of *T*. *cruzi* is a HLA-A\*0201-restricted peptide \[[@pone.0150996.ref021]\]. This peptide is recognized during the natural course of the disease and is presented by HLA-A molecules of the A2 supertype, such as HLA-A\*0205, HLA-A\*0222, HLA-A\*0226, HLA-A\*0259 and HLA-A\*0287 \[[@pone.0150996.ref022]\].

In the present study, the HLA-A2-restricted TcTLE peptide was observed to be presented by other HLA-A supertypes and able to induce functional activity in CD8^+^ T cells from these chagasic patients. Indeed, the finding that A24, A23 and A01 homozygous patients have TcTLE-specific CD8^+^ T cells demonstrated that several MHC supertypes present this peptide. TcTLE peptide-specific CD8^+^ T cells from non-HLA-A2 chagasic patients were also shown to be able to produce gamma interferon (IFN-γ), tumoral necrosis factor (TNFα), interleukin-2 (IL-2), perforin, and granzyme B and to express the proteins CD107a/b in response to TcTLE peptide stimulation.

Material and Methods {#sec005}
====================

Human study population {#sec006}
----------------------

Thirty-six chagasic patients from endemic areas of Colombia, including 13 males and 23 females with ages ranging from 19--76 years, were included in the study. All the subjects were recruited and clinically evaluated at the Hospital Universitario San Ignacio, Fundación Abood Clínica Shaio or Instituto Nacional de Salud in Bogotá, Colombia. All subjects were anti-*T*. *cruzi* antibody-positive according to both indirect immunofluorescence immunoassay (IFI) and enzyme-linked immunosorbent assay (ELISA) \[[@pone.0150996.ref023]\]. All chagasic patients were classified according to the Kuschnir grading system \[[@pone.0150996.ref024]\]. Fifteen patients were classified as non-cardiac chagasic patients or G0 stage (normal electrocardiogram (ECG) results), and twenty-one were classified as cardiac chronic chagasic patients (CCC) with different degrees of disease severity as follows: seven G1 with abnormal ECG results, seven G2 with abnormal ECG results and cardiac enlargement and seven G3 with abnormal ECG results, cardiac enlargement and clinical signs of heart failure. The group of healthy donors (HDs) consisted of fourteen seronegative individuals with similar ages to the chagasic donors who have always resided in non-endemic areas and who exhibited normal ECG results and clinical examination. All donors were volunteers, and they signed informed consent forms before being included in the study.

Approximately 20 mL of blood was collected from each individual by venipuncture as follows: 10 mL was collected in heparinized tubes for isolating peripheral blood mononuclear cells (PBMCs) by Ficoll-Paque PLUS density gradient centrifugation (GE Healthcare Bioscience, Uppsala, Sweden), 4 mL was collected in EDTA tubes for DNA extraction and 6 mL was collected for serological tests (Vacutainer, Becton-Dickinson, San José, CA, USA).

Ethics statement {#sec007}
----------------

This work was approved by the Research and Ethics Committees of the Facultad de Ciencias from the Pontificia Universidad Javeriana (6^th^ April 2011 and 17^th^ June 2009 CIEs). All adult subjects who participated in the study read, accepted and signed the informed consent form.

HLA-A2 typing by flow cytometry {#sec008}
-------------------------------

HLA-A2 typing was performed as previously described \[[@pone.0150996.ref022]\]. Briefly, 100 μL of peripheral blood was incubated with 0.25 μg of anti-HLA-A2 FITC antibody (clone BB7.2; BD Pharmingen, San Diego, CA, USA) for 20 minutes at 4°C \[[@pone.0150996.ref025]\]. After adding 500 μL of 1X lysis buffer (BD Bioscience, San José, CA, USA), the cells were incubated for 15 minutes at room temperature. Finally, the cells were washed with 1X phosphate-buffered saline (PBS; Eurobio, Les Ulis, France), and data were collected using a FACSAria II flow cytometer (BD Immunocytometry Systems, San José, CA, USA). The data were analyzed with FlowJo 9.3.2 software (Tree Star, Inc., Ashland, OR, USA).

HLA typing by SSP Unitray {#sec009}
-------------------------

HLA-A locus evaluation was performed using a commercial PCR kit based on sequence-specific primers (SSP-PCR) according to the manufacturer's instructions (Biotest, Landsteinerstr, Dreieich, Germany). Genomic DNA was extracted from each patient's peripheral blood using a GFX genomic blood DNA purification kit (Amersham Biosciences, Piscataway, NJ, USA). PCRs were conducted in a Stomacher 3500 Thermal Cycler PTC-100 (MJ Research, Inc., Watertown, MA, USA). The amplified products were resolved via 2% agarose gel electrophoresis and visualized following ethidium bromide staining. The amplified fragments were analyzed using Unimatch^TM^ 4.01 software (Invitrogen, Brown Deer, WI, USA). Once the alleles present in each individual were determined, medium-high-resolution typing was performed using A\*01, A\*03, A\*11, A19, A\*23, A\*24 or A\*68 SSP Unitray kits (Dynal Invitrogen Corporation, Brown Deer, WI, USA) according to the manufacturer's protocols.

Tetramer staining {#sec010}
-----------------

HLA-A2 PE-labeled tetramers loaded with TcTLE peptide (TLEEFSAKL), derived from *T*. *cruzi* KMP-11 protein \[[@pone.0150996.ref022]\], and also HLA-A2 PE-labeled tetramers with a modified Flu-MP peptide (Flu-MP\*; GILGFVTTL) derived from the influenza virus matrix protein \[[@pone.0150996.ref022],[@pone.0150996.ref026]\], and a modified CMV pp65 peptide (CMV\*; DLSPMVATV), employed as controls, were produced by the National Institute of Health (NIH) Tetramer Facility (Atlanta, GA, USA). In total, 1 × 10^6^ PBMCs per tube were stained with 0.5 μg/mL tetramers and anti-CD3-PerCP (clone SK7) and anti-CD8-FITC (clone SK1) conjugates (BD Biosciences, San José, CA, USA) for 20 minutes in the dark at room temperature. After the cells were washed with staining buffer (1% fetal bovine serum in 1X PBS), they were resuspended in 500 μL of 1X PBS. At least 50,000 events gated for CD3^+^ CD8^+^ T cells were acquired and analyzed using a FACSAria II flow cytometer (BD Immunocytometry Systems) and FlowJo 9.3.2 software (Tree Star, Inc.). The gating strategy is shown in [Fig 1A and 1B](#pone.0150996.g001){ref-type="fig"}. The cut-off point for HLA-A2/TcTLE tetramer CD8^+^ T cells was established at 0.063% after determining the average background value of K1-specific CD8^+^ T cells from HD (0.027%) plus three standard deviations (0.012%). A cut-off point for HLA-A2/Flu-MP\* and HLA-A2/CMV\* tetramer CD8^+^ T cells was fixed at 0.1% \[[@pone.0150996.ref026]\].

![Flow cytometry gating strategy and frequency of TcTLE-specific CD8^+^ T cells.\
Dot plots representative of the analysis of an HLA-A2-negative chagasic patient. (A) Lymphocytes were selected, and cell doublets were excluded from the analysis for the identification of CD8^+^ T cells based on the forward scatter area (FSC-A) and forward scatter height (FSC-H) (singlet 1), forward scatter width (FSC-W) and forward scatter height (FSC-H) (singlet 2), and side scatter width (SSC-W) and SSC-H characteristics (singlet 3). Finally, live CD3^+^ CD8^+^ cells were selected. (B) Selection of TcTLE peptide-specific CD8^+^ T cells by soluble tetramer assay. (C) Frequency of TcTLE peptide-specific CD8^+^ T cells from 20 HLA-A2-negative chronic chagasic patients. The cut-off point, which was fixed at 0.063, is indicated by the dotted line.](pone.0150996.g001){#pone.0150996.g001}

CD8^+^ T cell cytokine production and degranulation assays by flow cytometry {#sec011}
----------------------------------------------------------------------------

To assess T cell function, 1 × 10^6^ PBMCs were cultured with the TcTLE peptide (10 μg/mL) for 6 hours at 37°C and 5% CO~2~ in the presence of CD28 (1 μg/mL) and CD49d (1 μg/mL). After the cells were incubated for one hour, brefeldin A (1 μg/mL) and monensin (1 μg/mL) (BD Pharmingen) were added to the cultures. PBMCs were labeled with Live/Dead Fixable Aqua for 20 minutes in the dark at room temperature. Then, the cells were stained with anti-CD3 Pacific Blue (clone UCHT1) and anti-CD8 APC-H7 (clone SK1) monoclonal antibodies (BD Biosciences). The cells were permeabilized with Cytofix/Cytoperm (BD Pharmingen) and stained with anti-IL-2 PerCP-Cy5.5 (clone MQ1-17H12; BD Biosciences), anti-IFN-γ Alexa Fluor 700 (clone B27; BD Biosciences, San Jose, CA, USA), anti-TNFα APC (clone 6401.1111; BD Biosciences), anti-Perforin PE (clone B-D48; Abcam, Cambridge, MA, USA) and anti-Granzyme B Alexa Fluor 647 (clone GB11) conjugates (BD Biosciences) for 30 minutes at 4°C. To evaluate potential cytotoxic activity, anti-CD107a (clone H4A3) and CD107b FITC (clone H4B4) conjugates (BD Biosciences) were added to the PBMCs before stimulation. In each experiment, non-stimulated cells were used as a negative control, and staphylococcal enterotoxin B (SEB) (1.5 μg/mL) (Sigma-Aldrich, Saint Louis, MO, USA) was used as a positive control ([S1](#pone.0150996.s002){ref-type="supplementary-material"} and [S2](#pone.0150996.s003){ref-type="supplementary-material"} Tables). At least 50,000 events gated on live CD3^+^ CD8^+^ T cells were acquired using a FACSAria II flow cytometer (BD Immunocytometry Systems) and analyzed with FlowJo 9.3.2 software (Tree Star, Inc.). A positive cytokine response was defined by subtracting the background of cytokine production (cells cultured without antigen) and obtaining a value exceeding 0.05%; this frequency corresponds to the average frequency of CD8^+^ T cells producing cytokines from HDs cultured with the TcTLE peptide plus 3 standard deviations. Multifunctional analysis was performed using the Boolean gating strategy and visually represented with Pestle version 1.7 and SPICE software version 5.3 (provided by the NIH, Bethesda, MD, USA) \[[@pone.0150996.ref027]\].

Statistical analysis {#sec012}
--------------------

Differences between two groups were assessed using the Mann-Whitney test. Tests were two-tailed, and differences were considered statistically significant when *p* \< 0.05. GraphPad Prism version 6.0 for Mac OS X (GraphPad Software, San Diego, CA, USA) statistical software was used for statistical analyses.

Results {#sec013}
=======

TcTLE peptide: An epitope presented by several HLA-A supertypes {#sec014}
---------------------------------------------------------------

Previous studies of the KMP-11-derived TcTLE peptide revealed that it is efficiently processed, presented and recognized by CD8^+^ T cells in the context of the HLA-A\*0201 molecule during the natural course of Chagas disease \[[@pone.0150996.ref022],[@pone.0150996.ref028]\]. In addition, by applying a tetramer staining approach, the TcTLE peptide was observed to also be presented by other HLA-A2 alleles because it was recognized by CD8^+^ T cells from infected patients in the context of the HLA-A\*0205, HLA-A\*0222, HLA-A\*0226, HLA-A\*0259 and HLA-A\*0287 alleles \[[@pone.0150996.ref022]\]. Unexpectedly, when examining the frequency and functionality of TcTLE peptide-specific CD8^+^ T cells in a broader number of patients, twenty-eight of the thirty-six analyzed HLA-A2-negative chagasic patients were found to have CD8^+^ T cells that recognized the TcTLE peptide. Tetramer staining revealed that twenty of these patients had CD8^+^ T cells that were able to bind to the HLA-A2/K1-peptide tetramer at percentages ranging from 0.07--0.37% (median = 0.16%) ([Fig 1C](#pone.0150996.g001){ref-type="fig"} and [Table 1](#pone.0150996.t001){ref-type="table"}). The CD8^+^ T cells of the remaining eight patients were evaluated according to cytokine production and cytotoxic activity and were found to recognize the TcTLE peptide and to respond by producing cytokines or by exhibiting cytotoxic activity (see below). In order to evaluate the frequency of specific-CD8^+^ T cells of the irrelevant peptides, used as controls, the frequency of Flu-MP\* and CMV\* specific-CD8^+^ T cells was determined in the same assay conditions and with cells from the same patients. Indeed, it was found that although 11 out of 28 chagasic patients presented frequencies to both, TcTLE and Flu-MP\* peptides, 8 out of 28 only presented frequencies to TcTLE peptide and one patient (KT-059) only presented frequencies to Flu-MP\*. Additionally, the frequency of CD8^+^ T cells specific to CMV\* was determined in the QX-036 and QX-039 patients. The results showed that while the QX-036 patient had frequencies of CD8^+^ T cells specific to TcTLE and CMV\* peptides, the QX-039 patient only had frequencies of TcTLE peptide-specific CD8^+^ T cells. Together, these results demonstrate the specificity of the response.

10.1371/journal.pone.0150996.t001

###### Characteristics of HLA-A2^-^ individuals, the frequency of CD8^+^ T cells specific for the TcTLE peptide, and low-resolution typing of HLA-A alleles.

![](pone.0150996.t001){#pone.0150996.t001g}

  Patient code   Clinical status   Birthplace                                                    Gender   Age   Tetramer-specific CD8^+^ T cells (%)        HLA-A alleles              
  -------------- ----------------- ------------------------------------------------------------- -------- ----- ------------------------------------------- --------------- ---------- ----------
  KT-035         HD                Bogotá---Cundinamarca                                         F        37    0.03                                        0.03            ND         A23/A24
  KT-094         HD                Bogotá---Cundinamarca                                         M        67    0.03                                        0.02            ND         A24/A68
  KT-096         HD                Roldanillo---Valle                                            F        61    0.02                                        0               ND         A01/A24
  KT-097         HD                Barranquilla---Atlántico                                      F        19    0.04                                        0.03            ND         A24/A24
  KT-098         HD                Bogotá---Cundinamarca                                         F        58    0.01                                        0               ND         A30/A33
  KT-099         HD                Bogotá---Cundinamarca                                         M        44    0.01                                        0.04            ND         A03/A68
  KT-100         HD                Bogotá---Cundinamarca                                         F        39    0.02                                        0.05            ND         A24/A32
  KT-101         HD                Bogotá---Cundinamarca                                         F        65    0.04                                        0.01            ND         A24/A30
  CS-005         HD                Pasto---Nariño                                                F        26    0.04                                        ND              ND         A29/A31
  CS-007         HD                Bogotá---Cundinamarca                                         F        47    ND                                          ND              ND         A24/A24
  CS-016         HD                Bogotá---Cundinamarca                                         F        41    ND                                          ND              ND         A24/A68
  CS-017         HD                Bogotá---Cundinamarca                                         M        44    ND                                          ND              ND         A11/A33
  CS-018         HD                Bogotá---Cundinamarca                                         F        44    ND                                          ND              ND         A30/A33
  CS-040         HD                Medellín---Antioquia                                          M        58    ND                                          ND              ND         A03/A30
  KT-034         G0                Moniquirá---Boyacá                                            M        37    **0.37**                                    **0.29**        ND         A23/ A68
  QX-035         G0                Sucre---Santander                                             F        39    **0.28**                                    0.09            ND         A24/ A30
  QX-036         G0                Gachalá---Cundinamarca                                        F        44    **0.16**                                    0.09            **0.26**   A24/ A68
  QX-039         G0                Apulo---Cundinamarca[^a^](#t001fn002){ref-type="table-fn"}    F        54    **0.14**                                    0.08            0.03       A24/ A29
  KT-044         G0                Bogotá---Cundinamarca                                         M        19    **0.27**                                    **0.25**        ND         A24/A24
  KT-062         G0                Paéz---Boyacá                                                 F        28    0.04                                        0.05            ND         A11/A11
  KT 063         G0                Somondoco---Boyacá                                            M        57    **0.15**                                    0.06            ND         A11/ A68
  KT-069         G0                Capitancio---Santander                                        M        45    0.02                                        0.05            ND         A24/A31
  KT-073         G0                Miraflores---Boyacá                                           M        42    0.03                                        0.04            ND         A24/A30
  KT-081         G0                Paéz---Boyacá                                                 F        56    0.04                                        0.09            ND         A24/A68
  KT 087         G0                Bolivar---Santander                                           F        71    **0.13**                                    0.08            ND         A24/ A68
  KT 088         G0                Miraflores---Boyacá                                           M        60    **0.13**                                    0.09            ND         A24/A24
  KT 043         G1                Soata---Boyacá                                                M        61    **0.22**                                    **0.33**        ND         A23/ A68
  KT-050         G1                Miraflores---Boyacá                                           F        45    0.04                                        0.05            ND         A24/A31
  KT 067         G1                Ibagué---Tolima                                               M        41    **0.24**                                    **0.22**        ND         A01/ A31
  KT-068         G1                Gallegos---Santander                                          F        59    0.05                                        0.04            ND         A31/A68
  KT-071         G1                Rondón---Boyacá                                               M        38    0.03                                        0.05            ND         A24/A32
  KT 072         G1                Yopal---Casanare                                              F        52    **0.09**                                    **0.18**        ND         A23/A23
  KT 078         G1                El Engaño---Cundinamarca                                      F        60    **0.19**                                    **0.18**        ND         A01/ A29
  KT-039         G2                Soatá---Boyacá                                                F        67    **0.27**                                    **0.23**        ND         A24/A24
  KT-040         G2                Sutatenza---Boyacá                                            F        76    **0.07**                                    0.04            ND         A30/ A32
  KT-053         G2                Pajarito---Boyacá[^a^](#t001fn002){ref-type="table-fn"}       F        44    **0.13**                                    **0.12**        ND         A24/ A68
  KT-059         G2                San José de Pare---Boyacá                                     F        49    0.06                                        **0.11**        ND         A03/A32
  KT-061         G2                Berbeo---Boyacá                                               M        65    **0.22**                                    **0.15**        ND         A24/ A31
  KT-074         G2                San Joaquín---Santander                                       M        46    **0.09**                                    0.09            ND         A11/ A24
  KT-051         G3                Guamo---Tolima                                                F        58    **0.15**                                    **0.26**        ND         A11/ A23
  KT-058         G3                Armero---Tolima                                               F        39    **0.07**                                    0.08            ND         A24/ A68
  QX-062         G3                Zetaquirá---Boyacá                                            F        70    **0.25**                                    **0.22**        ND         A24/ A29
  QX-018         G0                Tablón---Togui-Boyacá[^a^](#t001fn002){ref-type="table-fn"}   F        35    ND [^b^](#t001fn003){ref-type="table-fn"}   ND              ND         A24/A24
  QX-045         G0                Santander---Belleza                                           F        32    ND [^b^](#t001fn003){ref-type="table-fn"}   ND              ND         A01/A01
  QX-050         G0                Chima---Santander                                             F        39    ND [^b^](#t001fn003){ref-type="table-fn"}   ND              ND         A03/A30
  QX-052         G2                Chitaraque---Boyacá                                           F        65    ND [^b^](#t001fn003){ref-type="table-fn"}   ND              ND         A29/A31
  QX-002         G3                Sabana larga---Casanare                                       M        65    ND [^b^](#t001fn003){ref-type="table-fn"}   ND              ND         A24/A31
  QX-031         G3                Soatá---Boyacá                                                F        55    ND [^b^](#t001fn003){ref-type="table-fn"}   ND              ND         A24/A24
  QX-051         G3                Chitaraque---Boyacá                                           F        55    ND [^b^](#t001fn003){ref-type="table-fn"}   ND              ND         A11/A24
  QX-054         G3                Fómeque---Cundinamarca                                        M        57    ND [^b^](#t001fn003){ref-type="table-fn"}   ND              ND         A24/A68

\* Indicates that peptides have a modification compared to original peptide

^a^ Indicates people who continued living in endemic areas. HDs: healthy donors; ND: not determined.

^b^ Indicates patients who have TcTLE-specific CD8^+^ T cells with cytokine production after TcTLE peptide stimulation.

Positive frequencies of specific CD8^+^ T cells are indicated in bold.

Based on these results, the HLA-A genotype of these twenty-eight patients ([Table 1](#pone.0150996.t001){ref-type="table"}) was confirmed by HLA-A locus PCR-SSP molecular typing. Seven of the twenty-eight (25%) tetramer- or cytokine/cytotoxic-positive chagasic patients had HLA-A homozygous alleles for A\*24 (five patients), A\*23 (one patient), and A\*01 (one patient) ([Table 1](#pone.0150996.t001){ref-type="table"}). Among the twenty-one HLA-A heterozygous patients, the most common alleles were A\*24 (57.1%) and A\*68 (38.0%), followed by A\*31, A\*11, A\*23, and A\*29 (20% each) ([Fig 2A](#pone.0150996.g002){ref-type="fig"} and [Table 1](#pone.0150996.t001){ref-type="table"}). All eight tetramer-negative patients showed a heterozygous pattern, with the most common allele being A\*24 (75% of the donors), followed by A\*31 (37.5%) and A\*68 (37.5%) ([Table 1](#pone.0150996.t001){ref-type="table"}). Two individuals of the HD group had HLA-A24 homozygous alleles, and A\*24 was the most common allele (57.0% of the donors) observed in a similar proportion of the chagasic patients ([Table 1](#pone.0150996.t001){ref-type="table"}).

![HLA typing of chronic chagasic patients with TcTLE-specific CD8^+^ T cells.\
HLA-A types (A) and sub-types (B) of chronic chagasic patients with TcTLE peptide-specific CD8^+^ T cells. The figure shows the number of patients with each HLA-A type and sub-type.](pone.0150996.g002){#pone.0150996.g002}

To determine the relationship between the HLA allele supertype and TcTLE recognition, tetramer- (twenty) or cytokine/cytotoxic-positive (eight) patients and healthy controls (twelve) were subjected to medium-high-resolution molecular typing ([Table 2](#pone.0150996.t002){ref-type="table"}). Seven HLA-A homozygous patients were identified: five A\*2402, one A\*2301 and one A\*0101. Note that the A\*2402 and A\*2301 alleles belong to the A24 supertype and that the A\*0101 allele belongs to the A1 supertype ([Fig 2B](#pone.0150996.g002){ref-type="fig"} and [Table 2](#pone.0150996.t002){ref-type="table"}). Additionally, 14 HLA-A heterozygous patients were found to have the A\*2402 allele (57.1%) in the absence of A\*6802 ([Fig 2B](#pone.0150996.g002){ref-type="fig"}), which belongs to the A2 supertype, the same supertype of the A\*0201 allele in which the TcTLE peptide presentation was first described. Indeed, the A\*2402 allele was the most frequent allele in the A\*24 individuals (94.1%), ([Fig 2B](#pone.0150996.g002){ref-type="fig"} and [Table 2](#pone.0150996.t002){ref-type="table"}). Additionally, two A1 supertype-allele members were detected in chagasic patients: one patient had A\*3002/A\*3201 and two patients had A\*0101 alleles, in the absence of any A2 or A24 supertype members ([Fig 2B](#pone.0150996.g002){ref-type="fig"} and [Table 2](#pone.0150996.t002){ref-type="table"}). In contrast, six of the eight A\*68 patients were A\*6802.

10.1371/journal.pone.0150996.t002

###### Medium-high-resolution HLA typing and supertype groups.

![](pone.0150996.t002){#pone.0150996.t002g}

  Patient code   HLA-A (SSP Unitray)   Types of HLA-A alleles   Supertype group   Patient code   HLA-A (SSP Unitray)   Types of HLA-A alleles   Supertype group
  -------------- --------------------- ------------------------ ----------------- -------------- --------------------- ------------------------ -----------------
  **KT-035**     A\*23                 A\*2301                  A24               **KT-058**     A\*24                 A\*2402                  A24
  A\*24          A\*2402               A24                      A\*68             A\*6802        A2                                             
  **KT-094**     A\*24                 A\*2403                  A24               **KT-061**     A\*24                 A\*2402                  A24
  A\*68          A\*6801               A3                       A\*31             A\*3101        A3                                             
  **KT-096**     A\*01                 A\*0101                  A1                **KT-063**     A\*11                 A\*1101                  A3
  A\*24          A\*2402               A24                      A\*68             A\*6802        A2                                             
  **KT-097**     A\*24                 A\*2414                  A24               **KT-067**     A\*01                 A\*0101                  A1
  A\*24          A\*2414               A24                      A\*31             A\*3109        A3                                             
  **KT-098**     A\*30                 A\*3002                  A1                **KT-072**     A\*23                 A\*2301                  A24
  A\*33          A\*3301               A3                       A\*23             A\*2301        A24                                            
  **KT-099**     A\*03                 A\*0301                  A3                **KT-074**     A\*11                 A\*1101                  A3
  A\*68          A\*6801               A3                       A\*24             A\*2402        A24                                            
  **KT-100**     A\*24                 A\*2404                  Unclassified      **KT-078**     A\*01                 A\*0101                  A1
  A\*30          A\*3001               A1/A3                    A\*29             A\*2904        Unclassified                                   
  **KT-101**     A\*24                 A\*2402                  A24               **KT-087**     A\*24                 A\*2402                  A24
  A\*30          A\*3001               A1/A3                    A\*68             A\*6801        A3                                             
  **CS-005**     A\*29                 A\*2903                  A1/A24            **KT-088**     A\*24                 A\*2402                  A24
  A\*31          A\*3101               A3                       A\*24             A\*2402        A24                                            
  **CS-007**     A\*24                 A\*2402                  A24               **QX-002**     A\*24                 A\*2402                  A24
  A\*24          A\*2402               A24                      A\*31             A\*3101        A3                                             
  **CS-016**     A\*24                 A\*2402                  A24               **QX-018**     A\*24                 A\*2402                  A24
  A\*68          A\*6801               A3                       A\*24             A\*2402        A24                                            
  **CS-017**     A\*11                 A\*1101                  A3                **QX-031**     A\*24                 A\*2402                  A24
  A\*33          A\*3301               A3                       A\*24             A\*2402        A24                                            
  **CS-018**     A\*30                 A\*3001                  A1/A3             **QX-035**     A\*24                 A\*2402                  A24
  A\*33          A\*3301               A3                       A\*30             A\*3010        Unclassified                                   
  **CS-040**     A\*03                 A\*0301                  A3                **QX-036**     A\*24                 A\*2402                  A24
  A\*30          A\*3004               A1                       A\*68             A\*6801        A3                                             
  **KT-034**     A\*23                 A\*2301                  A24               **QX-039**     A\*24                 A\*2402                  A24
  A\*68          A\*6802               A2                       A\*29             A\*2902        A1/A24                                         
  **KT-039**     A\*24                 A\*2402                  A24               **QX-045**     A\*01                 A\*0101                  A1
  A\*24          A\*2402               A24                      A\*01             A\*0101        A1                                             
  **KT-040**     A\*30                 A\*3002                  A1                **QX-050**     A\*03                 A\*0301                  A3
  A\*32          A\*3201               A1                       A\*30             A\*3001        A1/A3                                          
  **KT-043**     A\*23                 A\*2301                  A24               **QX-051**     A\*11                 A\*1101                  A3
  A\*68          A\*6802               A2                       A\*24             A\*2402        A24                                            
  **KT-044**     A\*24                 A\*2402                  A24               **QX-052**     A\*29                 A\*2902                  A1/A24
  A\*24          A\*2402               A24                      A\*31             A\*3101        A3                                             
  **KT-051**     A\*11                 A\*1101                  A3                **QX-054**     A\*24                 A\*2402                  A24
  A\*23          A\*2301               A24                      A\*68             A\*6802        A2                                             
  **KT-053**     A\*24                 A\*2414                  A24               **QX-062**     A\*24                 A\*2402                  A24
  A\*68          A\*6802               A2                       A\*29             A\*2902        A1/A24                                         

Functional activity of TcTLE peptide-specific CD8^+^ T cells in HLA-A2-negative (A24 and A1 supertypes) chagasic patients {#sec015}
-------------------------------------------------------------------------------------------------------------------------

To evaluate the functional activity of TcTLE peptide-specific CD8^+^ T cells from HLA-A2-negative patients with A24 or A1 supertypes, CD8^+^ T cells from twelve chronic chagasic patients were analyzed using six functional parameters after TcTLE peptide stimulation. Thus, the intracellular production of three cytokines (IFN-γ, TNFα and IL-2) and the potential cytotoxic activity, which was measured by evaluating CD107a/b expression as a marker of degranulation and intracellular perforin and granzyme B expression, were assessed.

The flow cytometric analysis strategy is shown in [Fig 3A](#pone.0150996.g003){ref-type="fig"}. Analysis of individual cytokine production showed that all chagasic patients had CD8^+^ T cells that produced at least one of these cytokines ([Table 3](#pone.0150996.t003){ref-type="table"}). As shown, one of twelve (8.3%) patients showed CD8^+^ T cells with only one or two effector functions, two patients (16.6%) showed three functions, three patients (25%) exhibited four functions, and four patients (33.3%) presented positive results for five of the six molecules tested. Cytokine-producing CD8^+^ T cells were not detected in HDs after antigenic stimulation ([Table 3](#pone.0150996.t003){ref-type="table"}).

![Polyfunctional profile of TcTLE-specific CD8^+^ T cell responses.\
(A) Functional cellular analysis of parasite-specific CD8^+^ T cells after stimulation with the TcTLE peptide. Gates were applied to identify cytokine-positive cells; these were defined according to the unstimulated samples for each subject. (B) The functional profiles of CD8^+^ T cells of HLA-A2-negative chagasic chronic patients were determined using a five-function detection method for CD107a/b, perforin, IFN-γ, IL-2 and TNFα after stimulation with the TcTLE peptide. The pie charts show the median percentages of responding CD8^+^ T cells grouped according to the number of simultaneous functions performed and color-coded depending on the functional profile. (C) Frequency of TcTLE-specific CD8^+^ T cells producing fifteen distinct combinations of five functions in non-CCC (white bars) and CCC patients (black bars). The results are shown as box-and-whisker (min-to-max) plots with median percentages of responding CD8^+^ T cells.](pone.0150996.g003){#pone.0150996.g003}

10.1371/journal.pone.0150996.t003

###### Frequency of cytokine response and cytotoxic activity after TcTLE peptide stimulation.

![](pone.0150996.t003){#pone.0150996.t003g}

  Patient code   Genotype              Clinical status    Frequency of cytokine production after TcTLE peptide stimulation [^a^](#t003fn001){ref-type="table-fn"}                                               
  -------------- --------------------- ------------------ --------------------------------------------------------------------------------------------------------- ---------- ---------- ---------- ---------- ----------
  CS-005         **A\*2903/A\*3101**   HD                 0                                                                                                         0.03       0.00       0.00       0.00       0.00
  CS-007         **A\*2402/A\*2402**   HD                 0.01                                                                                                      0.00       0.03       0.00       0.00       0.04
  CS-016         **A\*2402/A\*6801**   HD                 0.04                                                                                                      0.00       0.00       0.00       0.00       0.00
  CS-017         **A\*1101/A\*3301**   HD                 0.01                                                                                                      0.00       0.00       0.00       0.00       0.00
  CS-018         **A\*3001/A\*3301**   HD                 0.01                                                                                                      0.00       0.00       0.00       0.00       0.00
  CS-040         **A\*0301/A\*3004**   HD                 0.02                                                                                                      0.01       0.00       0.00       0.03       0.04
  QX-031         **A\*2402/A\*2402**   G0                 **0.57**                                                                                                  0.00       0.03       0.00       0.00       0.00
  QX-035         **A\*2402/A\*3010**   G0                 0.03                                                                                                      **0.90**   0.00       **3.70**   **2.40**   **0.07**
  QX-036         **A\*2402/A\*6801**   G0                 0.00                                                                                                      **0.07**   0.01       0.00       **1.10**   **0.60**
  QX-039         **A\*2402/A\*2902**   G0                 **0.47**                                                                                                  **0.15**   0.02       **8.60**   **2.30**   **0.22**
  QX-045         **A\*0101/A\*0101**   G0                 **0.09**                                                                                                  **0.19**   **0.09**   **2.50**   **0.80**   0.00
  QX-050         **A\*0301/A\*3001**   G0                 **0.36**                                                                                                  0.00       **0.11**   **2.45**   0.00       0.00
  QX-052         **A\*2902/A\*3101**   G2                 **0.62**                                                                                                  **0.56**   **0.07**   **3.60**   **0.07**   **0.76**
  QX-002         **A\*2402/A\*3101**   G3                 **0.10**                                                                                                  0.00       **0.09**   **2.37**   **5.70**   **0.41**
  QX-031         **A\*2402/A\*2402**   G3                 **0.45**                                                                                                  **0.52**   **0.40**   0.00       0.00       **0.18**
  QX-051         **A\*1101/A\*2402**   G3                 **0.59**                                                                                                  **0.09**   **0.32**   0.00       **0.10**   0.00
  QX-054         **A\*2402/A\*6802**   G3                 0.00                                                                                                      **0.33**   0.00       0.03       **4.80**   0.00
  QX-062         **A\*2402/A\*2902**   G3                 **0.49**                                                                                                  0.00       **0.10**   **1.29**   **2.60**   **0.50**

^a^ A positive cytokine response (bold) was defined as \> 0.05% after background (without antigen) subtraction.

Subsequently, CD8^+^ T cell polyfunctionality, which refers to simultaneous cytokine production and cytotoxic activity by a single cell, was evaluated. Five effector functions (IFN-γ, TNFα, IL-2, perforin and CD107a/b) were measured after peptide stimulation. No TcTLE-specific CD8^+^ T cells exhibited all five effector functions ([Fig 3B and 3C](#pone.0150996.g003){ref-type="fig"}) in non-cardiac or CCC patients. In contrast, the peptide-specific CD8^+^ T cells of CCC and non-CCC patients presented positive results for four, three and two of these functions ([Fig 3C](#pone.0150996.g003){ref-type="fig"}). Generally, non-CCC patients had a higher frequency of CD8^+^ T cells exhibiting four or two functions than those with cardiac manifestations. Thus, the most predominant profile including four positive effector functions was CD107a/b, IFN-γ, perforin and TNFα. In this case, although no significant differences were found, non-CCC patients tended to have more polyfunctional CD8^+^ T cells than did CCC patients. In contrast, specific CD8^+^ T cells with three positive functions were observed at similar frequencies in both patient groups. Although significant differences were not observed, the expression of IFN-γ and perforin was more frequent in non-CCC patients, whereas the production of CD107a/b and perforin was more frequent in CCC patients. Regarding monofunctional cells, TNFα and IFN-γ were the major cytokines produced by CD8^+^ T cells from non-CCC patients, and perforin was the most predominant functionality detected in CD8^+^ T cells from CCC patients ([Fig 3C](#pone.0150996.g003){ref-type="fig"}). Overall, these results demonstrate that TcTLE peptide-specific CD8^+^ T cells from HLA-A2 negative chagasic patients (specifically A24 and A1 supertypes) are functional.

Discussion {#sec016}
==========

Using experimental animal models, CD8^+^ T cells were demonstrated to be essential in controlling the spread of *T*. *cruzi* infection \[[@pone.0150996.ref003]--[@pone.0150996.ref008]\]. In addition, CD8^+^ T cells specific to *T*. *cruzi* antigens play an important role in protecting against *T*. *cruzi* infection in humans, and most of their epitopes are restricted to the HLA-A\*0201 allele. Thus, some A2-restricted epitopes have been extensively studied to explore their use in vaccine or immunotherapy design \[[@pone.0150996.ref029]--[@pone.0150996.ref032]\]. One of these epitopes, the TcTLE peptide, has been reported to be a promiscuous epitope presented in several alleles from the A2 supertype \[[@pone.0150996.ref022], [@pone.0150996.ref027]\]. In the in-depth study described here, the TcTLE peptide was also presented by other HLA-A alleles belonging to the A1 and A24 supertypes. Consequently, the functional activity of the TcTLE-specific CD8^+^ T cells from these HLA-A2-negative chronic chagasic patients was analyzed in terms of frequency and functionality, and its correlation with patient haplotype was assessed.

Several reports have described promiscuous T cell epitopes derived from infectious organisms, such as the dengue and Epstein-Barr (EBV) viruses, which are presented by more than one HLA-A allele and even by different HLA-A supertypes \[[@pone.0150996.ref017],[@pone.0150996.ref018]\]. For example, *Mongkolsapaya et al*. \[[@pone.0150996.ref018]\] reported the promiscuous presentation of an A\*2402-restricted epitope (from the A24 supertype) and an A\*1101 allele, classified in the A3 supertype. Additionally, *Liu et al*. \[[@pone.0150996.ref016]\] described various influenza A virus peptides capable of being presented by alleles belonging to the A24 and A3 supertypes. In this study, the promiscuous recognition of the TcTLE peptide among CD8^+^ T cells from chagasic donors having A1, A2 and A24 supertypes was detected. This phenomenon of presentation by different MHC supertypes has also been identified in tumor-derived peptides \[[@pone.0150996.ref020],[@pone.0150996.ref033]\].

Peptides from different pathogens presented in the context of homozygous HLA-A alleles confirmed the antigen presentation by alleles belonging to different supertypes. In *Mycobacterium tuberculosis*, peptides derived from the TB10.4 protein are presented by homozygous HLA-A\*3001 and A\*3002 alleles, which are recognized by peptide-specific CD8^+^ T cells from patients with active tuberculosis \[[@pone.0150996.ref034]\]. Cytomegalovirus AYAQKIFKIL- and PYLFWLAAI EBV-derived-peptides are presented by both HLA A\*2301 and A\*2402 alleles and generate a CTL response \[[@pone.0150996.ref035]\]. Similarly, the TcTLE peptide was presented by different homozygous HLA-A alleles, such as A\*0101 from the A1 supertype and A\*2301 and A\*2402 from the A24 supertype.

Although HLA-B and HLA-C alleles may also bind and present the TcTLE peptide, our results indicate that the TcTLE peptide was able to be presented by the HLA-A\*6802 allele from the A2 supertype, the supertype in which this peptide was originally described, and by other HLA-A alleles belonging to other supertypes, such as HLA-A\*0101, A\*3002, A\*3201 and A\*1101 of the A1 supertype) and A\*2301 and A\*2402 of the A24 supertype, which all generated measurable specific CD8^+^ T cell responses in *T*. *cruzi*-infected patients.

Using tetramer staining, CD8^+^ T cells from fifteen of nineteen (78.9%) HLA-A2-positive chagasic patients were previously shown to recognize the TcTLE peptide with tetramer frequencies ranging from 0.09% to 0.34% \[[@pone.0150996.ref022]\]. Similar percentages and frequencies are reported here: twenty of twenty-eight (71.4%) HLA-A2-negative chagasic patients had tetramer frequencies of 0.07‒0.37%. Consequently, antigen-specific CD8^+^ T cells from chronic chagasic patients recognized the TcTLE peptide independent of their HLA-A supertype, which indirectly indicates that the TcTLE peptide is presented by HLA-A alleles other than HLA-A2. Taken into account the published data \[[@pone.0150996.ref012],[@pone.0150996.ref036]--[@pone.0150996.ref041]\] summarized in [Table 4](#pone.0150996.t004){ref-type="table"}, the binding of the TcTLE (T**L**EEFSAK**L**) peptide to other alleles of the HLA-A1 and HLA-A24 supertypes is possible because the leucine (L) at 2 and 9 primary anchors positions of the TcTLE peptide bound to the B and F pockets of the MHC molecules of these supertypes ([Table 4](#pone.0150996.t004){ref-type="table"}). Regarding the Flu-MP\* peptide, previously we described that it is recognized by several alleles from the A2 supertype. The results of this work, suggest that this peptide could be also presented by other alleles from different supertypes. This possibility can be explained by the fact that the isoleucine (I) at 2 position and the leucine (L) at 9 position of the Flu-MP\* (G**I**LGFVTT**L**) peptide, fits in the B and F pockets of the alleles of these supertypes, respectively ([Table 4](#pone.0150996.t004){ref-type="table"}). However, this hypothesis should be confirmed.

10.1371/journal.pone.0150996.t004

###### Summary of primary anchors influences on the HLA-A2, A1 and A24 supertypes binding affinity.

![](pone.0150996.t004){#pone.0150996.t004g}

  Supertype   Allele(s)   Position 2 motif   Position 9 motif   References
  ----------- ----------- ------------------ ------------------ ---------------------------------------------------------------------------
  A2          A\*0201     LMV \[TQAI\]       VIL \[MTA\]        \[[@pone.0150996.ref012],[@pone.0150996.ref037]--[@pone.0150996.ref041]\]
  A\*6802                                                       
  A1          A\*0101     TI \[LMVS\]        FWY \[LV\]         \[[@pone.0150996.ref036],[@pone.0150996.ref038]--[@pone.0150996.ref040]\]
  A\*3201                                                       
  A24         A\*2402     YF \[LMVIT\]       FI \[WLMY\]        \[[@pone.0150996.ref036],[@pone.0150996.ref038]--[@pone.0150996.ref040]\]
  A\*2301                                                       

Amino acids listed in brackets are residues that are tolerated.

The analysis of individual cytokine production showed that all HLA-A2-negative chagasic patients had CD8^+^ T cells that produced at least one of the cytokines tested. This finding, together with the existence of polyfunctional CD8^+^ T cells in these HLA-A2-negative chagasic patients, allow us to propose that these CD8^+^ T cells from chronic chagasic patients belonging to the A24 and A1 supertypes are fully functional. Regarding the heterogeneous phenotype of the CD8^+^ T cells exhibiting the antagonistic functional activities associated with protection or pathogenesis, for instance, IFN-γ versus perforin \[[@pone.0150996.ref003]\], a larger sample size is needed to reach a conclusion concerning the role of heterogeneous phenotypes in disease control or progression. A similar requirement is suggested for assessing the role of the polyfunctional CD8^+^ T cells, which are usually associated with protection against chronic infections \[[@pone.0150996.ref042],[@pone.0150996.ref043]\]. Indeed, recent results from our group indicate that patients with less-severe disease have a higher frequency of polyfunctional CD8^+^ T cells, whereas patients at the advanced stage of the disease have a higher frequency of monofunctional CD8^+^ T cells \[[@pone.0150996.ref044]\]. The fact that the total parasite antigens, the KMP-11 protein \[[@pone.0150996.ref044]\] and the TcTLE peptide have revealed that the disease severity in cardiac chronic chagasic patients could be associated with a low frequency of polyfunctional CD8^+^ T cells, suggest that these markers could be evaluated for their use in the prediction of progression disease in accordance with the polyfunctional potential loss.

The promiscuity of the TcTLE peptide was observed both by soluble tetramers assays and cytokine production after peptide stimulation. Therefore, the cytokine production and the cytotoxic activity results reinforce the findings of TcTLE peptide promiscuity, according to the results found with tetramers. In addition, the frequency of TcTLE peptide-specific non-CD8^+^ T cells was evaluated and no frequencies of non-CD8^+^ T cells specific to this peptide were found ([S1 Fig](#pone.0150996.s001){ref-type="supplementary-material"}), finding that the tetramer binding is specific. Taking into account that subjects with ongoing chronic inflammation/immune stimulation due to chronic infections or inflammatory diseases are likely to have higher background staining with tetramer reagents, it is important to mention that we previously reported that patients with non-chagasic chronic heart diseases did not have significant frequencies of TcTLE peptide-specific CD8^+^ T cells \[[@pone.0150996.ref045]\]. However, other approaches as the use APCs consisting of HLA empty cell lines expressing only the HLA allele of interest could be used to further explore the specificity of HLA epitope restriction.

The most common HLA-A alleles in the Latin American population are as follows: HLA- A\*02 (28%), A\*24 (11%) and A\*68 (5%) in Brazil \[[@pone.0150996.ref046],[@pone.0150996.ref047]\]; A\*02 (50%), A\*24 (14%) and A\*68 (10%) in Bolivia \[[@pone.0150996.ref048]\]; A\*02 (63.4%), A\*30 (10.2%), A\*24 (6.6%) and A\*68 (5.4%) in Peru \[[@pone.0150996.ref049]\]; and HLA-A\*02 (25.5%), A\*24 (23%) and A\*68 (6.0%) in Colombia \[[@pone.0150996.ref050],[@pone.0150996.ref051]\]. Notably, these reports revealed that more than 45% of the Latin American population have HLA-A\*02, A\*24 or A\*68 HLA alleles; A\*02 was the original allele restriction reported for the TcTLE peptide \[[@pone.0150996.ref021],[@pone.0150996.ref022]\]. In this work, A\*24 and A\*68 alleles were also implicated in TcTLE presentation.

Consequently, a high percentage of the Latin American population has HLA-A alleles belonging to the A1, A2 and A24 supertypes, which are capable of presenting the TcTLE peptide and of inducing immune responses through effector functions and cytotoxic activities. Additionally, the TcTLE sequence is conserved among different parasite strains, particularly if it is also present in the KMP-11 protein from *Trypanosoma rangeli*, a synanthropic non-human pathogenic parasite \[[@pone.0150996.ref052]\]. Taken together, these results reasonably suggest that the TcTLE peptide, together with other parasite sequences \[[@pone.0150996.ref053],[@pone.0150996.ref054]\], could represent a potential target for vaccine or immunotherapy development against Chagas disease.

In summary, these results demonstrate that the TcTLE peptide epitope is recognized and presented by different HLA-A alleles from the A2, A24 and A1 supertypes and that it induces an immune response characterized by cytokine production and cytotoxic activity. This *T*. *cruzi*-derived peptide, which exhibits broad coverage of HLA presentation in the population, is a potential target for immunotherapy against Chagas disease.

Supporting Information {#sec017}
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###### Frequency of TcTLE-specific CD8^+^ T cells and non-CD8^+^ T cells.

Dot plots representative of the analysis of two HLA-A2-negative chagasic patients. Analysis were made on total CD3^+^ T cells to evaluated the frequency of TcTLE-specific CD8^+^ T cells and non-CD8^+^ T cells, and on total CD8^+^ T cells.

(TIF)
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Click here for additional data file.

###### Frequency of cytokine response and cytotoxic activity after culture without stimulation.
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Click here for additional data file.

###### Frequency of cytokine response and cytotoxic activity after SEB (positive control) stimulation.

(PDF)

###### 

Click here for additional data file.
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